Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of three active ingredients commonly used in the management of asthma and chronic obstructive pulmonary disease (COPD): beclomethasone dipropionate, salbutamol, and salmeterol. - Beclomethasone dipropionate is an inhaled corticosteroid that reduces airway inflammation by inhibiting multiple types of inflammatory cells and decreasing the production of mediators involved in the asthmatic response. - Salbutamol (also known as albuterol) is a short-acting beta-2 adrenergic receptor agonist that provides rapid bronchodilation by relaxing bronchial smooth muscle, offering quick relief from acute bronchospasm. - Salmeterol is a long-acting beta-2 adrenergic receptor agonist that maintains prolonged bronchodilation through sustained stimulation of beta-2 receptors on airway smooth muscle. The combination aims to provide both immediate symptom relief (via salbutamol), long-term bronchodilation (via salmeterol), and control underlying inflammation (via beclomethasone). This triple therapy approach may improve lung function, reduce exacerbations, and enhance overall asthma or COPD control compared to dual or monotherapy[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beclomethasone dipropionate + salbutamol + salmeterol.